Imatinib a Tyrosine Kinase Inhibitor: a potential treatment for SARS- COV-2 induced pneumonia

References

• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
   PubMed Web of Science ®Google Scholar
• Thompson BT, Chambers RC, Liu KD. Acute respiratory distress syndrome. N Engl J Med. 2017;377:562–572.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schoroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020 Mar 21.; published online. DOI:10.1161/CIRCULATIONAHA.120.046941.
   Web of Science ®Google Scholar
• Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020 Mar 27; DOI:10.1002/jmv.25785. Epub ahead of print. PMID: 32221983.
   Web of Science ®Google Scholar
• Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020 Mar 3.; published online. DOI:10.1007/s12250-020-00207-4
   Web of Science ®Google Scholar
• Morán G, Parra-Medina R, Cardona A, et al. Cytokines, chemokines and growth factors. El Rosario University Press; 2013. [cited 2020 Apr 1]. https://www.ncbi.nlm.nih.gov/books/NBK459450/
   Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China. Clin Immunol. 2020 Mar 25.;214:108393. published online.
   PubMed Web of Science ®Google Scholar
• Chen Z, Hu J, Zhang Z, et al. Efficacy of hydroxychloroquine in patients with COVID- 19: results of a randomized clinical trial. MedRxiv. 2020 April 10. doi:10.1101/2020.03.22.20040758.
   Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of Lopinavir–Ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 Mar 18.;382(19):1787–1799. published online.
   PubMed Web of Science ®Google Scholar
• Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395:473–475.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti- inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
   PubMed Web of Science ®Google Scholar
• Hunter T. Signaling–2000 and beyond. Cell. 2000;100:113–127.
   PubMed Web of Science ®Google Scholar
• Cohen P. Protein kinases — the major drug targets of the twenty-first century? Nat Rev Drug Discov. 2002;1(4):309–315.
   PubMed Web of Science ®Google Scholar
• Aschner Y, Downey GP. The Importance of Tyrosine Phosphorylation control of cellular signaling pathways in respiratory disease: pY and pY Not. Am J Respir Cell Mol Biol. 2018;59(5):535–547.
   Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031–1037.
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Dürnberger G, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and non kinase targets. Blood. 2007;110(12):4055–4063.
   PubMed Web of Science ®Google Scholar
• Rizzo AN, Sammani S, Esquinca AE, et al. Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2015;309(11):L1294–L1304.
   PubMed Web of Science ®Google Scholar
• Letsiou E, Rizzo A, Sammani S, et al. Differential and opposing effects of imatinib on LPS- and ventilator-induced lung injury. Am J Physiol Lung Cell Mol Physiol. 2014;308(3):L259–L269.
   Web of Science ®Google Scholar
• Aman J, van Bezu J, Damanafshan A, et al. Effective treatment of edema and endothelial barrier dysfunction with imatinib. Circulation. 2012;126:2728–2738.
   Google Scholar
• Stephens R, Servinsky L, Rentsendorj O, et al. Protein kinase g increases antioxidant function in lung microvascular endothelial cells by inhibiting the c-abl tyrosine kinase. Am J Physiol Cell Physiol. 2014;306(6):C559–C569.
   Web of Science ®Google Scholar
• Overbeek M, Van Nieuw Amerongen G, Boonstra A, et al. Possible role of imatinib in clinical pulmonary veno-occlusive disease. Eur Respir J. 2008;32:232–235.
   PubMed Web of Science ®Google Scholar
• Carnevale-Schianca F, Gallo S, Rota-Scalabrini D, et al. Complete resolution of life threatening bleomycin-induced pneumonitis after treatment with imatinib mesylate in a patient with Hodgkin’s lymphoma: hope for severe chemotherapy-induced toxicity? J Clin Oncol. 2011;29:e691–e693.
   PubMed Web of Science ®Google Scholar
• Aman J, Peters M, Weenink C, et al. Reversal of vascular leak with imatinib. Am J Respir Crit Care Med. 2013;188:1171–1173.
   Web of Science ®Google Scholar
• Cahill KN, Katz HR, Cui J, et al. Effect of KIT Inhibition by Imatinib on airway mast cells in patients with severe refractory asthma (KIA). J Allergy Clin Immunol. 2019;143(2):794–797.e10.
   Google Scholar
• Hoeper MM, Barst RJ, Bourge RC, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation. 2013;127(10):1128–1138.
   PubMed Web of Science ®Google Scholar
• Daniels CE, Lasky JA, Limper AH, et al. Imatinib treatment for Idiopathic Pulmonary Fibrosis randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010;181:604–610.
   PubMed Web of Science ®Google Scholar
• Coleman C, Sisk J, Mingo R, et al. Abelson Kinase inhibitors are potent inhibitors of severe acute respiratory syndrome coronavirus and middle east respiratory syndrome coronavirus fusion. J Virol. 2016;90(19):8924–8933.
   PubMed Web of Science ®Google Scholar
• Dyall J, Coleman C, Hart B, et al. Repurposing of clinically developed drugs for treatment of middle east respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014;58(8):4885–4893.
   PubMed Web of Science ®Google Scholar
• Peerzada M, Spiro T, Daw H. Pulmonary toxicities of tyrosine kinase inhibitors. Clin Adv Hematol Oncol. 2001;9(11):824–836.
   Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645–652.
   PubMed Web of Science ®Google Scholar
• Ohnishi K, Sakai F, Kudoh S, et al. Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia. 2006;20:1162–1164.
   PubMed Web of Science ®Google Scholar
• Patterson H, Nibbs R, McInnes I, et al. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases. Clin Exp Immunol. 2014;176:1–10. 163.
   PubMed Web of Science ®Google Scholar
• Thomas A, Rajan A, Giaccone G. Tyrosine kinase inhibitors in lung cancer. Hematol Oncol Clin North Am. 2012;26:589–605.
   Web of Science ®Google Scholar
• Richeldi L, Du Bois R, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
   PubMed Web of Science ®Google Scholar